INVITAE CORPORATION, A MEDICAL GENETICS COMPANY that had a $1.34 billion loss during the nine months ending Sept. 30, 2023, recently announced coming actions to cut costs and change operations. The San Francisco-based company sold “certain reproductive health assets including carrier screening and non-invasive prenatal screening” to Natera, an Austin, Texas-based company offering cell-free DNA […]
Invitae Cuts Costs to Rebuild Oncology Testing Pipeline
Divesture of assets and layoffs expected to result in nearly $100 million in savings
- By Robert Michel
- > From the Volume XXXI, No. 2 - February 5, 2024 Issue
- Tags: ArcherDx, BRCA1, BRCA2, Citizen, Comprehensive carrier screen, dna testing, Fierce Biotech, Genomic Health, Invitae, Ken Knight, Lynch syndrome, medical genetics oncology testing pipeline, Motley Fool, multiplex pcr, Natera, New York Stock Exchange, PCM, personalized cancer monitoring, reproductive health, The San Francisco Standard
